CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis - PubMed (original) (raw)
. 2016 Jul;39(7):1108-14.
doi: 10.2337/dc16-0330.
Affiliations
- PMID: 27289126
- DOI: 10.2337/dc16-0330
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis
Ele Ferrannini et al. Diabetes Care. 2016 Jul.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium-glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial-modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level-may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition-induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Comment in
- Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114.
Jordan J, El-Armouche A, Hanefeld M, Bornstein SR, Birkenfeld AL. Jordan J, et al. Diabetes Care. 2016 Dec;39(12):e224-e225. doi: 10.2337/dc16-1588. Diabetes Care. 2016. PMID: 27879363 No abstract available. - Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114.
Ferrannini E, Mark M, Mayoux E. Ferrannini E, et al. Diabetes Care. 2016 Dec;39(12):e226. doi: 10.2337/dci16-0033. Diabetes Care. 2016. PMID: 27879364 No abstract available. - Comment on Ferrannini et al. Diabetes Care 2016;39:1108-1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115-1122.
Ceriello A, Genovese S, Mannucci E, Gronda E. Ceriello A, et al. Diabetes Care. 2016 Nov;39(11):e195. doi: 10.2337/dc16-1332. Diabetes Care. 2016. PMID: 27926895 No abstract available. - Response to Comment on Ferrannini et al. Diabetes Care 2016;39:1108-1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115-1122.
Ferrannini E, Mark M, Mayoux E. Ferrannini E, et al. Diabetes Care. 2016 Nov;39(11):e196-e197. doi: 10.2337/dci16-0027. Diabetes Care. 2016. PMID: 27926896 No abstract available.
Similar articles
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
Mudaliar S, Alloju S, Henry RR. Mudaliar S, et al. Diabetes Care. 2016 Jul;39(7):1115-22. doi: 10.2337/dc16-0542. Diabetes Care. 2016. PMID: 27289124 - EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. Schernthaner G, et al. Clin Ther. 2016 Jun;38(6):1288-1298. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19. Clin Ther. 2016. PMID: 27210264 - EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L. Perreault L. Am J Med. 2017 Jun;130(6S):S51-S56. doi: 10.1016/j.amjmed.2017.04.005. Am J Med. 2017. PMID: 28526185 - EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L. Perreault L. Am J Cardiol. 2017 Jul 1;120(1S):S48-S52. doi: 10.1016/j.amjcard.2017.05.010. Epub 2017 May 17. Am J Cardiol. 2017. PMID: 28606344 Review. - Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
Tanaka A, Node K. Tanaka A, et al. J Cardiol. 2017 Mar;69(3):501-507. doi: 10.1016/j.jjcc.2016.10.019. Epub 2016 Dec 30. J Cardiol. 2017. PMID: 28043708 Review.
Cited by
- The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review.
Stachteas P, Nasoufidou A, Karagiannidis E, Patoulias D, Karakasis P, Alexiou S, Samaras A, Zormpas G, Stavropoulos G, Tsalikakis D, Kassimis G, Papadopoulos C, Fragakis N. Stachteas P, et al. J Clin Med. 2024 Sep 12;13(18):5408. doi: 10.3390/jcm13185408. J Clin Med. 2024. PMID: 39336895 Free PMC article. Review. - Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis.
Hou J, Ren L, Hou Q, Jia X, Mei Z, Xu J, Yang Z, Li Y, Yan C. Hou J, et al. Front Cardiovasc Med. 2024 Sep 11;11:1388337. doi: 10.3389/fcvm.2024.1388337. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39323760 Free PMC article. - New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.
El Khayari A, Hakam SM, Malka G, Rochette L, El Fatimy R. El Khayari A, et al. Genes Dis. 2023 Nov 23;11(6):101174. doi: 10.1016/j.gendis.2023.101174. eCollection 2024 Nov. Genes Dis. 2023. PMID: 39224109 Free PMC article. Review. - Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment.
Rudzki G, Knop-Chodyła K, Piasecka Z, Kochanowska-Mazurek A, Głaz A, Wesołek-Bielaska E, Woźniak M. Rudzki G, et al. Pharmaceuticals (Basel). 2024 Jul 26;17(8):987. doi: 10.3390/ph17080987. Pharmaceuticals (Basel). 2024. PMID: 39204092 Free PMC article. Review. - Ketones and the cardiovascular system.
Lopaschuk GD, Dyck JRB. Lopaschuk GD, et al. Nat Cardiovasc Res. 2023 May;2(5):425-437. doi: 10.1038/s44161-023-00259-1. Epub 2023 Apr 10. Nat Cardiovasc Res. 2023. PMID: 39196044 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical